Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs

References

• Abdul MI, Jiang X, Williams KM, et al. (2010). Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol 69:508–15
   PubMed Web of Science ®Google Scholar
• Albers GW, Atwood JE, Hirsh J, et al. (1991). Stroke prevention in nonvalvular atrial fibrillation. Ann Int Med 115:727–36
   PubMed Web of Science ®Google Scholar
• Amlani S, Nadarajah T, Afzal R, et al. (2010). Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. J Thromb Thrombolysis 30:434–40
   PubMed Web of Science ®Google Scholar
• Banfield C, O'Reilly R, Chan E, Rowland M. (1983). Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol 16:669–75
   PubMed Web of Science ®Google Scholar
• Bellec G, Dreano Y, Lozach P, et al. (1996). Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis 17:2029–34
   PubMed Web of Science ®Google Scholar
• Black DJ, Kunze KL, Wienkers LC, et al. (1996). Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 24:422–8
   PubMed Web of Science ®Google Scholar
• Bochner F, Siebert DM, Rodgers SE, et al. (1989). Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. Thromb Haemost 61:211–16
   PubMed Web of Science ®Google Scholar
• Buckley NA, Dawson AH. (1992). Drug interactions with warfarin. Med J Aust 157:479–83
   PubMed Web of Science ®Google Scholar
• Cham BE, Ross-Lee L, Bochner F, Imhoff DM. (1980). Measurement and pharmacokinetics of acetylsalicylic acid by a novel high performance liquid chromatographic assay. Ther Drug Monit 2:365–72
   PubMed Web of Science ®Google Scholar
• Coudray C, Talla M, Martin S, et al. (1995). High-performance liquid chromatography-electrochemical determination of salicylate hydroxylation products as an in vivo marker of oxidative stress. Anal Biochem 227:101–11
   PubMed Web of Science ®Google Scholar
• Dentali F, Douketis JD, Lim W, Crowther M. (2007). Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 167:117–24
   PubMed Web of Science ®Google Scholar
• Dupont I, Berthou F, Bodenez P, et al. (1999). Involvement of cytochromes P-450 2E1 and 3A4 in the 5-hydroxylation of salicylate in humans. Drug Metab Dispos 27:322–6
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, O'Donnell M. (2009). Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 120:2006–11
   PubMed Web of Science ®Google Scholar
• Fiore LD, Ezekowitz MD, Brophy MT, et al. (2002). Department of veterans affairs cooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 105:557–63
   PubMed Web of Science ®Google Scholar
• Fiske WD, Connell JM, Benedek IH. (1995). Lack of pharmacokinetic interaction between aspirin and warfarin. Am J Ther 2:407–13
   PubMedGoogle Scholar
• Gorelick PB. (2007). Combining aspirin with oral anticoagulant therapy: is this a safe and effective practice in patients with atrial fibrillation? Stroke 38:1652–4
   PubMed Web of Science ®Google Scholar
• Goren A, Liu X, Gupta S, et al. (2015). Warfarin and aspirin use for stroke prevention among patients with atrial fibrillation: The US national health and wellness survey. Am J Ther 22:248–56
   PubMed Web of Science ®Google Scholar
• Hart RG, Tonarelli SB, Pearce LA. (2005). Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 36:1588–93
   PubMed Web of Science ®Google Scholar
• Higgs GA, Salmon JA, Henderson B, Vane JR. (1987). Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci USA 84:1417–20
   PubMed Web of Science ®Google Scholar
• Hurlen M, Abdelnoor M, Smith P, et al. (2002). Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347:969–74
   PubMed Web of Science ®Google Scholar
• Jiang X, Williams KM, Liauw WS, et al. (2005). Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 59:425–32
   PubMed Web of Science ®Google Scholar
• Johnson SG, Rogers K, Delate T, Witt DM. (2008). Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 133:948–54
   PubMed Web of Science ®Google Scholar
• Johnson SG, Witt DM, Eddy TR, Delate T. (2007). Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service. Chest 131:1500–7
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Zhang ZY. (1997). Human P450 metabolism of warfarin. Pharmacol Ther 73:67–74
   PubMed Web of Science ®Google Scholar
• Krishna Kumar D, Gopal Shewade D, Parasuraman S, et al. (2013). Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. J Young Pharm 5:13–17
   PubMedGoogle Scholar
• Leonards JR. (1962). Presence of acetylsalicylic acid in plasma following oral ingestion of aspirin. Proc Soc Exp Biol Med 110:304–8
   PubMed Web of Science ®Google Scholar
• Lewis HD Jr, Davis JW, Archibald DG, et al. (1983). Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309:396–403
   Google Scholar
• Malhotra B, Alvey C, Gong J, et al. (2011). Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Br J Clin Pharmacol 72:257–62
   PubMed Web of Science ®Google Scholar
• Mirsen TR, Hachinski VC. (1988). Transient ischemic attacks and stroke. CMAJ 138:1099–105
   PubMed Web of Science ®Google Scholar
• Mohapatra R, Tran M, Gore JM, Spencer FA. (2005). A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era. Am Heart J 150:19–26
   PubMed Web of Science ®Google Scholar
• O'Reilly RA, Trager WF, Motley CH, Howald W. (1980). Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man. J Clin Invest 65:746–53
   PubMed Web of Science ®Google Scholar
• Palareti G, Legnani C. (1996). Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 30:300–13
   PubMed Web of Science ®Google Scholar
• Patrono C, Rodriguez LAG, Landolfi R, Baigent C. (2005). Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373–83
   PubMed Web of Science ®Google Scholar
• Rost S, Fregin A, Ivaskevicius V, et al. (2004). Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537–41
   PubMed Web of Science ®Google Scholar
• Salem DN, O'Gara PT, Madias C, Pauker SG, American college of chest physicians. (2008). Valvular and structural heart disease: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:593S–629S
   PubMed Web of Science ®Google Scholar
• Shen CL, Huang XH, Huang JH, et al. (2013). Development and validation of a RP-HPLC method for simultaneous determination of warfarin enantiomers, aspirin and salicylic acid in beagle plasma: application to pharmacokinetic study. Lat Am J Pharm 32:679–87
   Web of Science ®Google Scholar
• Toyoda K, Yasaka M, Iwade K, et al. (2008). Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke 39:1740–5
   PubMed Web of Science ®Google Scholar
• van Es RF, Jonker JJ, Verheugt FW, et al. Antithrombotics in the secondary prevention of events in coronary thrombosis-2 research G. (2002). Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360:109–13
   PubMed Web of Science ®Google Scholar
• Wittkowsky AK. (2003). Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 3:221–30
   PubMedGoogle Scholar